METHOD OF PREPARING INDOLIN-2-ONE COMPOUND AND METHOD OF USING INDOLIN-2-ONE

20240043383 ยท 2024-02-08

    Inventors

    Cpc classification

    International classification

    Abstract

    A compound, having a structure represented by a formula (I),

    ##STR00001##

    and prepared by one pot synthesis of benzophenone hydrazone, 7-chloroisatin, and copper(II) acetate monohydrate, and refluxing in 100 mL of anhydrous methanol solvent for 48 hrs. A method for preparing the compound includes: collecting and placing 0.0235 g of benzophenone hydrazone, 0.6914 g of 7-chloroisatin, and 0.6720 g of copper(II) acetate monohydrate complex in a 100.0 mL flask; adding 50 mL of anhydrous methanol as a solvent; stirring a resulting mixture at room temperature for 48 hrs; performing column chromatography separation, and elution with petroleum ether/dichloromethane in a volume ratio of 1:1, and collecting final component points and naturally volatilizing the final component points to obtain 7(E)-chloro-3-diphenylmethylindolin-2-one crystals. The compound is used as a catalyst for reaction between benzophenone imine and trimethylsilonitrile, and has a catalytic effect with a conversion rate reaching 99%.

    Claims

    1. A compound, having a structure represented by a formula (I), ##STR00004## and prepared by one-pot synthesis of benzophenone hydrazone, 7-chloroisatin, and copper(II) acetate monohydrate, and refluxing in 100 mL of anhydrous methanol solvent for 48 hrs.

    2. The compound of claim 1, prepared into a form of a crystal, wherein when being diffracted with a CuK ray, which is monochromated by a graphite monochromator and has a wavelength of =1.54184 on an Oxford X-ray single crystal diffractometer at a temperature of 293(2)K, the crystal of the compound belongs to a monoclinic system, 12/a, and has cell parameters as follows: a=16.9274(3) , alpha=90 deg; b=10.18017(18) , beta=99.926(2) deg; c=20.2755(4) , gamma=90 deg.

    3. A method for preparing a compound having a structure represented by a formula (I), ##STR00005## the method comprising: collecting and placing 0.0235 g of benzophenone hydrazone, 0.6914 g of 7-chloroisatin, and 0.6720 g of copper(II) acetate monohydrate complex in a 100.0 mL flask; adding 50 mL of anhydrous methanol as a solvent; stirring a resulting mixture at room temperature for 48 hrs; performing column chromatography separation, and elution with petroleum ether/dichloromethane in a volume ratio of 1:1; and collecting final component points and naturally volatilizing the final component points to obtain 7(E)-chloro-3-diphenylmethylindolin-2-one crystals.

    4. (canceled)

    Description

    BRIEF DESCRIPTION OF THE DRAWINGS

    [0011] The sole figure is a single crystal diffraction pattern of the target product benzophenone-7-chloroisatin azine.

    DETAILED DESCRIPTION OF THE EMBODIMENTS

    [0012] To further illustrate the present application, experiments detailing preparation and use of (E)-chloro-3-diphenylmethyleneindolin-2-one are described below. It should be noted that the following examples are intended to describe and not to limit the present application.

    Example 1. Preparation of (E)-chloro-3-diphenylmethyleneindolin-2-one

    [0013] Under an anhydrous and anaerobic condition, 0.0235 g of benzophenone hydrazone, 1.0 g of 7-chloroisatin, and 0.6720 g of copper (II) acetate monohydrate complex were collected and added into a 100 mL two-mouth flask. 50 mL anhydrous methanol was added as a solvent, and stirred at room temperature for 48 hrs. Column chromatography separation was performed, petroleum ether/dichloromethane (having a volume ratio of 1/1) was used for elusion, and final component points were collected and naturally volatilized to obtain 7(E)-chloro-3-diphenylmethyleneindolin-2-one crystals, which have a yield of 82%; red-brown crystals, and a melting point>200 C.; 1H NMR (500 MHz, 298K, CDCl3) ppm 10.9 (s, 1H) 7.76-7.78 (m, 2H, ArH), 7.62 (d, J=7.5 Hz, ArH), 7.41-7.54 (m, 7H), 7.41 (d, J=8.2 Hz, 1H), 7.19 (d, J=7.3 Hz, 1H), 13C{1H} NMR (125 MHz, 298K, CDCl3) 164.6, 158.5, 146.2, 142.0, 138.1, 136.5, 134.0, 132.8, 130.8, 129.9, 129.2(2), 129.0(2), 128.6 (2), 128.2(2), 125.9, 123.5, 118.5, 115.9; HRMS (EI) m/z (%) calcd for C.sub.21H.sub.14N.sub.3OCl 360.0896; found: 359.8130; v.sub.max (cm.sup.1) 3084, 1725, 1615, 1583, 1475, 1442, 1432, 1400, 1317, 1328, 1317, 1299, 1222, 1170, 1137, 1072, 1031, 1072, 1009, 1000, 948, 931, 910, 836, 796, 796, 766, 757, 732, 664, 652, 593, 558;

    [0014] Data of nitrogen compound crystal data are as follows:

    TABLE-US-00001 TABLE 2 Typical bond length data of crystal Empirical formula C21H14N3OCl Molecular weight 359.80 Temperature 293(2) K wavelength 1.54184 Crystal system, space group Monoclinic, 12/a Unit cell dimensions a = 16.9274(3) = 90. b = 10.18017(18) = 99.926 (2) . c = 20.2755(4) = 90 volume 3441.64 (11) .sup.3 charge density 8, 1.389 Mg/m.sup.3 Absorption correction 2.083 mm.sup.1 parameter Number of electrons 252 in a unit cell Crystal size 0.22 0.18 0.15 mm Theta range 8.856 to 145.756 Collection range of 20 <= h <= 20, 11 < HKL's indicator k <= 12, 18 < 1 <= 24 Reflections collected/unique 6937/3338[R(int) = 0.0228] Absorption correction method Multi-layer scanning Refinement method Full-matrix least-square on F.sup.2 Data number/restraint number/ 3338/0/235 parameter number Refinement method 1.047 Uniformity factor of R.sub.1 = 0.0358, wR.sub.2 = 0.0929 diffraction point Observable diffraction fit factor R.sub.1 = 0.0416, wR.sub.2 = 0.0997 Largest peak and hole on the 0.17 and 0.23 e..sup.3 difference Fourier diagram

    TABLE-US-00002 TABLE 4 Bond Lengths for lm-12-yellow_autored. Atom Atom Length/ Atom Atom Length/ C11 C1 1.7267(16) C7 C8 1.5094(18) O1 C8 1.2213(17) C10 C15 1.391(2) N1 C6 1.3971(17) C10 C11 1.403(2) N1 C8 1.3613(19) C4 C3 1.388(2) N2 N3 1.3568(17) C15 C14 1.383(2) N2 C7 1.2836(19) C11 C12 1.379(2) N3 C9 1.2832(18) C21 C20 1.388(2) C9 C16 1.4940(19) C1 C2 1.397(2) C9 C10 1.4777(19) C2 C3 1.378(3) C5 C6 1.403(2) C17 C18 1.389(3) C5 C7 1.457(2) C20 C19 1.367(3) C5 C4 1.3938(19) C12 C13 1.381(3) C6 C1 1.376(2) C18 C19 1.382(3) C16 C21 1.388(2) C13 C14 1.376(3) C16 C17 1.385(2)

    TABLE-US-00003 TABLE 3 Typical bond length data of crystal text missing or illegible when filed text missing or illegible when filed indicates data missing or illegible when filed

    TABLE-US-00004 TABLE 5 Bond Angles for lm-12-yellow_autored. Atom Atom Atom Angle/ Atom Atom Atom Angle/ C8 N1 C6 111.02(12) C11 C10 C9 120.67(13) C7 N2 N3 117.42(13) O1 C8 N1 126.47(13) C9 N3 N2 121.83(12) O1 C8 C7 127.57(14) N3 C9 C16 122.71(13) N1 C8 C7 105.95(12) N3 C9 C10 116.86(13) C3 C4 C5 118.23(15) C10 C9 C16 120.39(12) C14 C15 C10 120.54(16) C6 C5 C7 105.88(12) C12 C11 C10 120.38(15) C4 C5 C6 120.23(14) C16 C21 C20 120.49(16) C4 C5 C7 133.90(14) C6 C1 Cl1 119.98(12) N1 C6 C5 110.52(12) C6 C1 C2 118.56(14) C1 C6 N1 128.51(14) C2 C1 Cl1 121.45(12) C1 C6 C5 120.97(13) C3 C2 C1 120.59(15) C21 C16 C9 119.13(13) C16 C17 C18 120.06(16) C17 C16 C9 121.70(13) C2 C3 C4 121.41(14) C17 C16 C21 119.17(14) C19 C20 C21 119.99(17) N2 C7 C5 133.56(13) C11 C12 C13 120.40(16) N2 C7 C8 119.90(13) C19 C18 C17 120.05(17) C5 C7 C8 106.53(12) C20 C19 C18 120.24(16) C15 C10 C9 120.90(13) C14 C13 C12 119.73(16) C15 C10 C11 118.43(14) C13 C14 C15 120.52(16)

    Example 2. Use of Target Compound (I) in Nitrile Silylation Reaction of

    [0015] ##STR00003##

    [0016] 0.1 mmol of a complex was collected and added into a 25 mL small flask, 2 mL of anhydrous methanol was added, then 1.0 mmol of benzophenone imine and 0.3 mL of trimethylsilonitrile were added to the solution, and stirred at room temperature for 15 hrs. After that, .sup.1HNMR detection was performed, and a catalytic conversion was 75%. .sup.1H NMR (600 MHz, CDCl.sub.3, 27 C.) 7.23-7.59 (m, 10H) , 4.10 (s, 2H).

    [0017] Unless otherwise indicated, the numerical ranges involved in the present application include the end values. While particular embodiments of the present application have been shown and described, it will be obvious to those skilled in the art that changes and modifications may be made without departing from the present application in its broader aspects, and therefore, the aim in the appended claims is to cover all such changes and modifications as fall within the true spirit and scope of the present application.